About Michael Silber

This author has not yet filled in any details.
So far Michael Silber has created 1944 blog entries.

Indiana

Health Coverage Program (IHCP) provided Pharmacy updates approved by Drug Utilization Review Board May 2024. 

Also in Indiana, the Family and Social Services (FSSA) is launching a new Medicaid program called Indiana PathWays for Aging starting July 1.

Finally in Indiana, IHCP (Health Coverage Program) issued a bulletin correcting errors on Vaccine for Children (VFC) vaccine administration codes. 

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2024-06-06T16:05:44-04:00June 6, 2024|Indiana|

Kentucky

Effective June 1, 2024, the Department for Medicaid Services made changes to the vaccine coverage for Medicaid Fee-for-Service members.  

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2024-06-06T16:04:30-04:00June 6, 2024|Kentucky|

Louisiana

The legislature adjourned sine die on June 3. 

Also in Louisiana, several bills’ pharmacies supported passed both houses and were sent to Gov. Jeff Landry (R) to be signed into law.   

HB 579 Allows pharmacists to test and treat for PEP/PrEP (See NACDS’ letter to the governor supporting enactment of this legislation.) 

SB 444 Prohibits reimbursement below cost 

HB 603 – PBM audits 

SB 281 – PBM Enforcement and audits 

Finally in Louisiana, the Department of Health issued the preferred drug list update for July 1, 2024. 

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2024-06-06T16:04:00-04:00June 6, 2024|Louisiana|

Maryland

The Prescription Drug Affordability Board (PDAB) announced the June virtual meeting of its Stakeholder Council, scheduled for 2:00 pm on June 24. The agenda and other meeting materials will be available on the Stakeholder Council page of the PDAB’s website prior to the scheduled meeting. To register for the June 24 virtual meeting, please click on this link and enter the required information. After registering, you will receive a confirmation email containing details about joining the meeting. Also, to register for oral public comment and for additional information concerning public comments, please refer to the Stakeholder Council page.

Also in Maryland, please visit the Prescription Drug Affordability Board’s, Cost Review Study Process page on the Board’s website to learn more about the comment period for “Board Selected Drugs for Cost Review.” The 60-day comment period will close on July 22, 2024.  

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2024-06-06T16:03:16-04:00June 6, 2024|Maryland|

Massachusetts

MassHealth published its June All Provider Bulletin 391” with orders ALL 361, ALL 376 and ALL 380 announcing the start dates for enforcing the ordering, referring and prescribing (ORP) requirements. With the exception of the information in the bulletin, all information in ALL 361, ALL 376 and ALL 380 remains in effect. Opportunity for payment of claims initially denied due to unenrolled ORP provider as described in ALL 376, billing providers should take certain steps to avoid claim denials due to unenrolled ORP providers. If a claim is denied because of an unenrolled or unauthorized ORP provider on or after June 9, 2024, the claim will be placed in suspense status. The claims system will continue to check to see if the ORP provider has enrolled with MassHealth for up to 90 days after the first date of service on the claim. Once the ORP provider is enrolled, the claim will then be payable. This will allow billing providers time to follow the steps related to unenrolled ORP providers outlined in ALL 376. If the ORP provider is not enrolled by 90 days from the first date of service on the claim, the claim will be denied. Also, effective June 9, 2024, billing providers can resubmit claims that were previously denied due to an unenrolled or unauthorized ORP provider if the first date of service on the claim is no earlier than September 1, 2023. If the ORP provider is enrolled with MassHealth within 90 days of the first date of service on the claim, the claim will be payable. 

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

2024-06-06T16:02:46-04:00June 6, 2024|Massachusetts|

Michigan

Pharmacy Controlled Substance Administrative Rules have been revised and changes are effective as of May 31, 2024. One amendment of note is the removal of Gabapentin, meaning it is no longer classified as a controlled substance in the state. A prescriber without a controlled substance license can now prescribe Gabapentin, and Gabapentin no longer needs to be included in reporting to the Michigan Automated Prescription System (MAPS).

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2024-06-06T16:02:13-04:00June 6, 2024|Michigan|

Missouri

The Department of Social Services, MO HealthNet Division (MHD), reminded covered entities to comply with all the Health Resources and Services Administration (HRSA) 340B Program rules, including the exclusion of using 340B stock for inpatient administration and the prohibition of duplicate discounts.

Also in Missouri, to raise awareness about Project Hep Cure, Josh Moore, the Director of Pharmacy at MO HealthNet, sent a message to healthcare providers on how to help cure Missourians of the disease. 

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2024-06-06T16:01:43-04:00June 6, 2024|Missouri|

Oklahoma

The legislature adjourned sine die on May 30.

SB 232, legislation allowing pharmacists to screen and treat for minor ailments and other conditions, dispense hormonal contraceptives without a prescription and increase the pharmacy technician ratio from two to three, died due to the early adjournment of the legislature.

Two PBM reform bills that pharmacies supported because they enhanced the Attorney General’s enforcement authority, addressed MAC pricing and audits, were enacted into law. SB 1670 / HB 3376 

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2024-06-06T16:01:02-04:00June 6, 2024|Oklahoma|
Go to Top